Iterum Therapeutics PLC

Iterum Therapeutics plc is a pharmaceutical company that develops and commercializes treatments for drug-resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations, for uncomplicated and complicated urinary tract infections, complicated intra-abdominal infections, community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.